Skip to main content

Table 3 Comparison of GMTs, GMIs and seroconversion rates of poliovirus type-specific neutralizing antibodies after vaccination between maternal antibody negative and positive participants

From: The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines

Group Type GMT (95% CI) GMI (95% CI) Seroconversion rate (%)
Maternal negative Maternal positive P Maternal negative Maternal positive P Maternal negative Maternal positive P
1 I 5086.27 (3909.17–6617.80) 3191.30 (2619.36–3888.12) 0.006 1271.57 (977.29–1654.45) 111.56 (81.88–152.00) < 0.001 100.00 98.78 1.000
II 878.35 (704.86–1094.54) 505.09 (381.51–668.70) 0.002 219.59 (176.21–273.63) 24.32 (15.51–38.11) < 0.001 100.00 85.71 0.008
III 1142.55 (961.97–1357.03) 619.06 (386.93–990.46) 0.017 285.64 (240.49–339.26) 31.13 (15.56–62.31) < 0.001 100.00 82.76 0.001
2 I 4231.17 (3210.69–5576.00) 3139.05 (2554.03–3858.08) 0.084 1057.79 (802.67–1394.00) 111.75 (88.66–154.84) < 0.001 100.00 98.98 1.000
II 900.64 (767.91–1056.30) 550.11 (405.38–746.52) 0.005 225.16 (191.98–264.07) 30.25 (18.80–48.67) < 0.001 100.00 90.70 0.023
III 1036.17 (880.40–1219.50) 564.94 (372.86–855.96) 0.003 259.04 (220.10–304.87) 29.60 (12.55–69.80) < 0.001 100.00 86.96 0.006
3 I 6187.48 (4563.25–8389.85) 4131.94 (3411.86–5003.98) 0.025 1546.87 (1140.81–2097.46) 123.79 (86.99–176.17) < 0.001 100.00 96.67 0.556
II 1018.74 (873.77–1187.76) 711.84 (567.01–893.67) 0.008 254.69 (218.44–296.94) 43.10 (29.34–63.29) < 0.001 100.00 95.65 0.129
III 1207.23 (1025.79–1420.76) 835.86 (475.52–1469.29) 0.206 301.81 (256.45–355.19) 27.66 (10.49–72.96) < 0.001 100.00 85.71 0.004
4 I 5830.71 (4431.70–7671.36) 3051.49 (2523.95–3689.29) 0.001 1457.68 (1107.92–1917.84) 88.46 (64.22–121.86) < 0.001 100.00 95.83 0.574
II 273.86 (225.62–332.42) 228.21 (171.48–303.71) 0.276 68.47 (56.41–83.10) 16.22 (11.10–23.71) < 0.001 100.00 89.36 0.014
III 675.19 (561.49–811.92) 260.20 (178.35–379.61) < 0.001 168.80 (140.37–202.98) 11.08 (6.12–20.05) < 0.001 100.00 84.85 0.001
5 I 546.12 (408.61–729.91) 660.98 (549.64–794.86) 0.306 136.53 (102.15–182.48) 19.40 (14.51–25.95) < 0.001 100.00 88.42 0.122
II 209.42 (176.39–248.63) 122.10 (97.10–153.55) < 0.001 52.35 (44.10–62.16) 7.62 (5.36–10.82) < 0.001 100.00 78.26 < 0.001
III 501.89 (417.41–603.47) 567.52 (397.01–811.27) 0.518 125.47 (104.35–150.87) 36.94 (24.12–56.56) < 0.001 100.00 100.00 –
  1. Group 1: low-dose Sabin IPV group. Group 2: medium-dose Sabin IPV group. Group 3: high-dose Sabin IPV group. Group 4: control Sabin IPV group. Group 5: control Salk IPV group
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us